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The contact phase of blood coagulation results in activated factor XI.1'2
After that the reaction sequence leading to thrombin formation is as follows:
XIr
IX----+ IXu
IXa + VIII * ph.lip. + Ca++= "tenase"
tenase
x - x a
Xa + V * ph.lip. * Ca++= "prothrombinase"
"prothrombinase"
[-II" (:thrombin).
Two features characterize this scheme:
1. The cascade sequence: the product of one reaction is (part of) the
enzyme in the next.3, 4
2. The complex enzymes. Bsth the factor X-activating enzyme ("tenase")
and the thrombin-forming enzyme ("prothrombinase") consist of two proteins
(clotting factors) adsorbed to a phospholipid.
The activated forms of factor IX and factor X are serine proteases.5-8 As
such, they have hardly any tenase or prothrombinase activity.e-l3 To obtain
this activity two other components are necessary: another protein (factor VIII
or factor V, respectively) and a phospholipid, or rather, a micelle composed
of a mixture of phospholipids.
The prevailing model of prothrombinase is the following: at the surface of
a phospholipid micelle, factor Xu and factor V adsorb next to each other. At
the same interphase the substrate, prothrombin, adsorbs. The active site in
factor Xu attacks the vulnerable sites in prothrombin and so generates thrombin.
The evidence leading to this model is the following: 1) The proteins can
be shown to adsorb onto the micelles. Activity generates when both adsorb
onto the same micelle. Ca++ is necessaiy for the adsorption of factor Xo but
counteracts the adsorption of factor V. Optimal activity is found when about
equimolar quantities of both factor adsorb.l0' 11,14-20 The dependence of the
activity on the concentrations of the constituent moieties is in accordance with
the following reaction scheme' zr, zz
Xo * Ca+* * ph.lip * X, - Ca- ph.lip.
V*ph . l i p .=V-ph . l i p .
V + Xo - Ca - ph.lip. + prothrombinase
Xo * Ca*' + V - ph.lip. = prothrombinase
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For tenase, an analogous set of experiments has been carried out. Adsorp-
tion and Ca** dependence 20' 23-25 adsorption on the same micelle 26 and the
kinetics of the generation of activity2T indicate a comparable reaction scheme:
IXu * Ca++ * ph.lip. + Dq - Ca - ph.lip.
VIII + ph.lip. + VIII - ph.lip.
VIII + IX" - Ca - ph.lip. = tenase
IXu * Ca++ + VIII - ph.lip. + tenase
We can elaborate upon this model on the basis of the existing evidence obtained
on its various components.
Tne Acrryn Srre-BBlnrNc PnoruNs (Fecron X, eNo Fecron IXu)
Both active site-bearing proteins are two-chain serine proteases.5-8 The
heavy chain shows extensive homologies to other members of the chymotrypsin
family and contains the active serine.
The light chain is particularly interesting in that it contains several pairs of
y-COOH glutamyl residues. The dicarboxyl side chains generated bind
Ca++28' 2s and via Ca** bind to the phospholipid surface.so The study of the
function of these groups in coagulation is facilitated by the fact that both factor
IX and factor X (and factor II as well) have been demonstrated to exist in a
form without carboxylated glutamic acids.3l' 3z The carboxylation of the glu-
tamic acids is brought about by a vitamin K-dependent enzyme system. Con-
sequently, in vitamin K deficiency or during administration of vitamin K an-
tagonists, no carboxylation takes place. In that case, the uncarboxylated form
of the protein comes into the circulation. These proteins induced by vitamin K
absence (c.q. Antagonists) (PIVKAs) have no normal procoagulant function.
Indeed, we discovered them a3 because they inhibit coagulation under certain
circumstances. Recently, we isolated PIVKA-X, i.e. the uncarboxylated factor
X from anticoagulated cows.sa Like factor X, it can be activated by a protease
from Russell's viper venom. Toward small synthetic substrates it shows estero-
lytic and peptidolytic activity similar to that of factor Xu. Like factor X" it
splits prothrombin in free solution. Unlike factor X, this activity cannot be
enhanced by the addition of Ca*-, factor V, and phospholipid.3a It thus seems
that its active site, as well as its vulnerable site, is intact. but that due to an
inability to bind to phospholipid it cannot partake in the normally active pro-
thrombinase. Indeed, the only difference between the PIVKAs and the normal
factors lies in the 7-carboxylation as has been demonstrated by Stenflo.28' 2e T{e
found 7-COOH groups as the only chemical difference between PIVKA-II and
prothrombin. It is further emphasized by our recent finding that PIVKA-II
can be converted into prothrombin in a vitamin K-dependent oxidative car-
boxylation by an enzyme system isolated from liver microsomes (Tnnrn 1).
Tne Pen.rnNzyMES (Fecrons V eNt VI[)
The function of the factors V and VIII is much less clear than those of the
active site-bearing factors. Both factor V and factor VIII lack any known
enzymatic property of their own.35-38 Both occur in plasma as polymers; both
are rendered more active by thrombin. Thrombin has been shown to favor the
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conversion of native factor V in more active moieties of /+ of the original
molecular weight, although small molecular weight factor V does occur without
the action of thrombin, and then is also active. Thrombin-activated factor V
readily inactivates in a reaction that is a dimerization or a higher order polym-
erization.a0 This suggests the following reactions:
vt s= 4v-.e 
thrombin, 
4v-." ?2 vi.
t : tetramer; m : monomer; e : enhanced activity; i: inactive species'
The relative activities before and after thrombin action are unknown. some
Tesre 1
CONWnSTON On PrVre-II rNrO PnOrnnOivtBIN IN A CELL-FREE Sysrelvt 
*
Component
Synthesis
when Omitted Replacement
Synthesis
when
Replaced
Microsomal protein
Supernatant
PIVKA-II
Vitamin K' (0.3 mM)
(4  mM)
( 1 . 5  m M )
Creatine Phosphate (5 mM)
f phosphokinase
HCO; (13 mM)
O"
thromboplastin
prothrombin
Warfarin (0.1 mM)
Ca (4 mM)
ADP (1 .5  mM)
Co;-(13 mM)
Nz
Mg
ATP
4
J '
0
J J
0
22
89
3
5
0
0
0
80
1 1
38
* The activities are expressed as percentages of the synthesis rate in the complete
mixture, i.e.,2 nM/hr. the complite system consists of: microsomal proteins, 0'2
b-O* unlt.;'microsomal supernat-ant, OD* units; PMA-II, 0'16 units'/ml; Tris
HCi pH 8.j, 50 mM; SucroG, 60 mM; and KCl, 30 mM. Thromboplastin (if present)
iOE" ,tu Factor II (if present),0.008 Units/ml, which causes a comparable clotting
time as 0.16 U/ml of PWKA-II. Mixtures of 0.1 ml were incubated for I hr at37" C,
diluted fourfold and assayed for factor II activity. The increase between the factor
II activity at t:0 and t:60 min was a measure for the factor II synthesis. Microso-
mai protiins were partly purified on DEAE cellulose. PMA-II was partly purified
on Q-AE Sephadex and'adsorbed three times with an excess of Basol to remove the
last traces of factor II.
reversibility of the inactivation has been demonstrated. It has also been demon-
strated thai the adsorption of factor v onto phospholipid enhances the adsorp-
tion of factor Xu. An interaction between factor v and factor Xu on the
phospholipid surfice is thus probable. This may also be deduced from the obser-
vation ttral prothrombinase ;d tenase develop slowly when a large phospholipid
surface is ohered.rr, 2? This rnay be interpreted as being due to a small chance
for the two factors to interact, but persistent activity after interaction has taken
place; i.e., the equilibrium in the formation of the complex must be at the side
of the complex.
The bibchemistry of factor vIII is even more complicated than that of
factOr V. As yet, no coherent picture of its mode of conversion and action can
\
I
t
Hemker et al.: Phospholipid Surfaces 1.01
be given. The reader is referred to a recent review for further information.al
Both factor V and factor VIII do adsorb on hydrophobic powders. Factor
V has been shown to retain a good deal of its activity when adsorbed, but will
not elute from the powder.a2 This, together with the data on the influence of
Ca*-ions suggests that the binding of factor V to phospholipid may also be
hydrophobic.
It has been demonstrated that factor V has a special affinity for a fragment
of the prothrombin molecule.a3 Since factors V and VIII have no enzymatic
activity of their own but specifically modify the enzyme with which they come
in contact, we baptized them paraenTymes.
Ttre Sussrnere
The substrate of prothrombinase is prothrombin. Prothrombinase brings
about two cleavages of the primary structure, one at the Arg 373-Ile 374 bond.
The active site-bearing B-chain of thrombin thus comes into being. The other
is the Arg 274-Thr 275 bond that splits off thrombin a- and B-chain from the
prothrombin molecule. The remainder of the molecule (the "pro"-part) contains
the Ca+ and phospholipid-binding site; it can be again split by thrombin.aa-48
PIVKA-II, which does not bind to phospholipid, is not a suitable substrate
for prothrombinase, although it does contain normal thrombin as and will react
like normal prothrombin when activated in free solution, either by proteolysis
(Ecarinuo) or by stoichiometric complexation with staphylocoagulase and
subsequent change of tertiary structure.5l
Factor X has been reported not to bind to phospholipid, but when it is
activated, it does. It is not yet known if PIVKA-X is activated by "tenase."
Trre PsospnoLIPID
Two types of protein-lipid interaction seem to be necessary: interaction of
charged groups via Ca++ and hydrophobic interaction. The charge of the
micelles will influence the possibilities for both Ca+ ions and charged proteins
to approach the micelle and to attach to its surface by electrostatic forces. Since
it has been shown that hydrophobic interactions do play a role too, the micelle
also has to offer the possibility of hydrophobic interactions. Any micelle will
do this, but to what extent depends on faity acid chain length in the phospho-
lipid as well as on the nature of the head groups. Therefore, apart from charge,
hydrophobiciry of the micelle will play a role in determining its coagulation
activity.
The experiments on the formation of prothrombinase and tenase suggest
that the lateral mobility of the adsorbed proteins will influence the activity of
the enzymes.zz This mobility will change with the "phase" of the micelle phos-
pholipids; i.e., liquid, liquid crystalline, or solid. The phase at the ambient
temperature is a function of the composition of the micelle.
Thus there are at least three properties of the micelle that will determine
its effectiveness in these enzyme complexes: phase, hydrophobicity, and charge.
All three vary with the composition of the micelle. This may explain why, in
binary mixtures of pure phospholipids, there is a definite composition with
optimal activity. sz-ss
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The Role of the Phospholipid Surface
One can imagine at least three possible roles for the phospholipid 
surface
in tr*-!*.iution"of prothrombinase and tenase: 1) an increase in 
local con-
centrat ion;z)areouct ionof thedegreesof f reedomofthemovementsof the
p.ot"l" ';and.3)inductionoffavorablechangesintertiarystructure'' 
Inrr|o* in Local Concen*atiore' The ioncentration of any protein 
at an
interphase will be determined by the concentration of that protein 
in the sur-
rounding solution ano its affinity for the interphase. Proteins with a high 
affinity
loi u 
""ituin 
type of interphase will concentrate at that interphase._ In fact, it
h;. t; .no*r, tt ut the concentration of clotting factors at.the thrombocyte
,*ru"" is high. one in-every thousand or.ten-thousand protein_molecules 
that
a clotting factor meets is irr! purt"er for its function irr coagulation. 
A local
enrichment in concentration tierefore seems essential. Yet there 
is reason to
doubt that local co.rceniJion is the only factor involved, because 
1) factor V
enhances the adsorptio; ;il;;t X", so there exists a cooperative 
interaction
ofin"r. proteins; i"a il phillipin will interacr with lipids.in such 
a way as to
""tu"""ihe 
adsorptiorr'oi 
"toitl"g 
factors but diminish its procoagulant ac-
tivitY.se-sz
Local concentration at an interphase is a concept that should be 
used with
some caution, because itr" u*o.utt'of reacting species per unit volume 
is hardly
a useful figure in thi, ;;;;;t. The possibili-ty of interaction of 
the molecules
l, aetermliea Uy tte umo,rnt p", ,"'fu"" and ihe mobility when 
adsorbed (c'q'
,i" ifr" zuia phase). Moreovtr, orientation effects will modify the 
percentage
oi-""tiog, tirat lead to a reaction. This automatically leads to 
the following:
A Reduction of the Degrees ol Freedom ol the Movements ol 
the Proteins'
The active site of uo 
".rf*. 
and the vulnerable site of its protein substrate
toil o"rv a small fraction of its total surface. A small portion oJ the 
collisions
io f."" *l rtio.r will therefore be effective. when enzyme and 
substrate are
adso rbeda tan in te rphasebyaspec i f i cpo r t i ono f the i rmo lecu le theya re
orientated, and only a fiaction of ttreir surfices can meet. Favorable 
orientation
can enhance ttre posrititJy lftut ttt" meeting surface contains the 
active and
*f"".utf. sites. 
'ihis o.i".ttutioo effect can be eveo more Pronounced when a
third molecule, the p".u"*y.", brings about an orientation of 
substrate and
"*V."" 
in the pfurr" oiiil'i"t"rpnurl". There has recently been a discussion
about the possibility tt"t ""t."pyihanggs. 
favoring the "best fit".position could
account for the n""f uOi".1-eii of po-sitions jusibefore the 
collision between
enzyme and substrate.- i[i* "trt.opy 
change_would correspond-to free energy
;;;;; in vttrattonat a"e;"", "t 
ii"eaoml It was concluded that in bulk the
translat ionaldegreesof f reedomrepresent toomuchenergytoal loyth isk ind
of regulation. These t*"rrutio"ur eirergies, however, are considerably 
lower for
molecules adsorbed to an interfac". w" are at present investigating 
the possi-
bilities that in that cal ifti. 
-;"nttop' 
mechanism" might function. (W. T'
flermens, unPublished results. )
Induct ionofFavorableChonS"sinTert iaryStructure ' .Changesinter t iary
structure will accompa; ;"t ;d;tption o-f a protein' That they 
are favorable
in our case and if so, t"i *irit extent, is difficuli to assess at this 
moment. One
Joo trot conclude from kinetic measurements that changes occur 
that are not
;;tiy ;"*r.itf". ffrir -""'u"ir- is of prime interesi in the 
generation of
contact product, U"t ii, tot" i" the generition of tenase and 
prothrombinase
waits for further elucidation.
l1
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DISCUSSION
Dn. RosnxseRc: I think Dr. Hemker has pointed out the importance of
cofactors in the coagulation mechanism. I might start out the discussion by
asking both Dr. Ratnoff and Er. Kaplan the following question: It seems to
me that the high molecular weight kininogenJow molecular weight kininogen
transition is a very critical one in allowing factor XII to activate its various
substrates. We know that most of the kininogen circulates in the low molecular
weight or inactive form. What do you think is responsible for running this
process, and what effect does it have on the contact with blood?
Dn. RnrNorn: That's a charmingly easy question to answer. I don't know,
but I would like to talk a little about high molecular weight kininogen. In my
paper, I cut out description of an experiment that was close to but not identical
with the one that Dr. Kaplan described; and I might say that his data and ours
are in agreement about most things. The experiment that I didn't show runs
something like this. Plasma kallikrein, as was first shown by others, digests a
synthetic amide, and the result is a beautiful yellow color. This, I assume, is
the same substrate used by Dr. Kaplan. Kallikrein will do this in a pure system
in which you just have kallikrein and the substrate. The presence or absence
of high molecular weight kininogen doesn't particularly matter. Now, kallikrein
adsorbs onto insoluble substances, and it does this better than Hageman factor
does. In its adsorbed state, kallikrein is a very poor digestor of this synthetic
substrate. It's as if-perhaps as Dr. Hemker suggests-some of those active
groups are turned upside down and can't get out. If one first treats the kaolin,
the activator of Hageman factor (but there is no Hageman factor in this system
now), and treats it with Fitzgerald factor, this kaolin-treated Fitzgerald factor
will no longer inactivate plasma kallikrein. Prevention of inactivation thus
looks like activation. I think, to get back to the last sentence of my talk, every-
thing that Dr. Kaplan and I have been talking about is artifactual. In real life
we haven't any idea how these agents interreact, and we know that we're
missing the point because patients lacking Hageman factor, the Fitzgerald
factor, and Fletcher factor are asymptomatic. Whales live out their whole long
life times without any Hageman factor or any Fletcher factor.
Dn. KepreN: There is so far no evidence that one can convert the high
molecular weight kininogen to the low in a simple enzymatic way. The high is
a substrate of plasma kallikrein. Nobody has succeeded yet in converting high
molecular weight kininogen into low by digesting it with kallikrein; so one of
the questions is: Are these two proteins synthesized by the same gene? Anti-
body to low molecular weight kininogen gives a complete line of identity with
the high, so the structure of the low is essentially contained within the high,
which would make you think that it's not synthesized by two genes. Tagged
high molecular weight kininogen added to plasma shows no conversion to the
low molecular weight kininogen, so there is no obvious proteolytic process, at
least in plasma, by which the high is converted to the low. Finally, I would
like to put forth the following notion: we know that to make an IgG molecule
you have to have a minimum of four genes-two for the light chain and two
for the heavy chain. The light chain is about 22,500 molecular weight. There
is a gene for the antibody-binding region and a gene for the constant region,
and somehow these are put together at the transcription level or the translation
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level. I would wonder whether, in fact, there is not one gene for low molecular
weight kininogen and another gene for the part of the high that differs, and that
the two are put together to form the high molecular weight kininogen; but
there would be an excess on the part of the one that makes low, and that's what
we see in the plasma. It is interesting to note that some of the patients with
high molecular weight kininogen deficiency, like our patients, have no kininogen
at all, zero high and zero low. But in the Fitzgerald patient, I believe total
kininogen is almost 507o, yet all of it is the low form. So maybe he has that
part of it but is completely missing the other half.
Dn. VnorvreN: How can we explain that the phospholipid micelles even
when suspended in a lot of plasma protein to begin with, still seem to adsorb
selectively only a couple of protein species during clotting? Do you presume
that there is displacement of other proteins when you start adding calcium, for
example, in your system? How can trace proteins such as factors VIII and IX
compete with abundant proteins such as albumin and globulins?
Dn. Her'mnn: I think they would compete because of their equilibrium
constants between their concentration in a free solution and the concentration
adsorbed. I think there is a clear indication that at least the factors II, VII,
IX, and X are provided with a specific binding group to bind to these phos-
pholipids.
Dn. B. ArrxaxoBn (New York Blood Center, New York, N.Y.): Dr.
Hemker, there has been no allusion to the action of naturally occurring deter-
gent agents such as bile salts. Would you care to speculate as to their possible
role regarding the lipid micelles and their possible role in activation of some
of the clotting factols.
Dn. HBvrxpn: I have actually avoided discussing all types of physical and
physicochemical circumstances that do alter the phospholipid surface, because
things really get complicated.
Dn. Nossnr: There has been some suggestion that platelets may activate
the Hageman factor system, and I wonder if Dr. Kaplan or Dr. Ratnoff has
any sentiments about that phenomenon.
Dn. RerNorr: I suppose I have sentiments about everything. But as far
as I know, the experiments by Dr. Walsh to which you refer have not been
confirmed anywhere. And, as far as I know, there is no firm evidence that
platelets will activate Hageman factor or PTA, in the presence or absence of
ADP.
Dn. Nossrr: Does anybody want to contradict that?
Dn. RlrNonn: Just remember I said "as far as I know." I didn't say it
wasn't true.
Dn. Wsrss: We have tried to either confirm or not confirm Peter Walsh's
studies, and we've had both some success on one hand and no success on the
other. The contact system is activated by kaolin more readily in the presence
of platelets than in the absence of platelets. However, we could not do the
same with collagen.
Dn. RerNonn: Could we talk a little bit about terminology? High molecu-
lar weight kininogen, to the extent that we know at this point, is identical with
the term "Fitzgerald factor," defined as being an agent missing in Fitzgerald
trait. There are four other families that have been described in which high
molecular weight kininogen is deficient. Three of these four families at least
have a defect qualitatively different from Fitzgerald trait. The patients with
William's trait lack not only high molecular weight kininogen-that is, Fitz-
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saiil. The same is true of a family'of a patient narned Flaujeac, lacking both
high and low rnoiecular weight kininogen, and. this, has' been ieferred to as
"Flaujeac trait." The same is also true of the patients named Washington in
Cincinnati described as having Fitzgerald trait, but in fact deficient both in the
high molecular weight kininogen-that is, the Fitzgerald factor-and in low
molecular weight kininogen. Hopefully, my colleagues and I will drop this
rather charming nomenclature and stick to high and low rnolecular weight and
combined kininogen defi ciencies.
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